Clinical Trials Browser

Has results × Small Cell Lung Carcinoma × durvalumab × Clear all

NCT04745689 2026-04-24

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03043872 2026-04-22

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Small Cell Lung Carcinoma

NCT04951115 2024-11-26

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Phase 2 Terminated

6 enrolled 13 charts

Small Cell Lung Carcinoma

NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2 Terminated

3 enrolled 13 charts

Brain Neoplasms, Small Cell Lung Carcinoma

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

18 enrolled 13 charts

Small Cell Lung Carcinoma